Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein ( CETP ) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB , Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Apolipoprotein | Products > Signaling Pathways > LDLR | Products > Signaling Pathways > LPL Receptor | Products > Signaling Pathways > CETP
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye